Trials / Withdrawn
WithdrawnNCT06434103
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
An Open, Multicenter Phase I/II Trial of SHR-A1921 in Combination With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A trial to evaluate the tolerability and efficacy of SHR-A1921 in combination with adbelizumab and SHR-8068 with or without carboplatin in patients with advanced non-small cell lung cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1921；Adebrelimab；SHR-8068；carboplatin | SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days. |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2024-10-10
- Completion
- 2024-10-10
- First posted
- 2024-05-30
- Last updated
- 2026-04-08
Source: ClinicalTrials.gov record NCT06434103. Inclusion in this directory is not an endorsement.